Archive for the 'Cancer drugs' Category
The cancer drug cyclophosphamide activates a viral infection that helps anti-viral medications eliminate a virus-linked cancer, says a new study.
The drug is used to treat Burkitt lymphoma, an aggressive, fast-growing type of non-Hodgkin lymphoma that often occurs in children. In Africa, the cancer is caused by the Epstein-Barr virus (EBV), which typically remains dormant inside [...]
April 25th, 2010 | Posted in Cancer drugs | No Comments
The European Commission has referred GlaxoSmithKline Plc’s breast cancer treatment Tyverb back for a fresh assessment by drugs regulators following new data from Europe’s biggest pharmaceuticals company.
Glaxo said on Tuesday that Tyverb, which is already on sale in the United States under the name Tykerb, had been referred back to the EU’s Committee for Medicinal [...]
March 18th, 2008 | Posted in Cancer drugs, Drugs and Medications, GlaxoSmithCline | No Comments
Spectrum Pharmaceuticals, Inc. today announced that it has received marketing approval from the U.S. Food and Drug Administration (FDA) for Levoleucovorin for Injection. It is indicated after high-dose methotrexate therapy in patients with osteosarcoma, and to diminish the toxicity and counteract the effects of impaired methotrexate elimination or inadvertent overdose of folic acid antagonists. LEVOleucovorin [...]
March 9th, 2008 | Posted in Cancer drugs, Drugs and Medications, New drugs | No Comments
A drugs firm asked Indian officials for permission Thursday to make cheaper generic copies of cancer drugs for export to poor countries in a case watched closely by global pharmaceutical giants.
Indian firm Natco Pharmaceuticals made the plea for the country’s first so-called “compulsory licence” to the patent office as it bids to make generic copies [...]
February 28th, 2008 | Posted in Cancer drugs, Drug makers, Drugs and Medications, Generic drugs | No Comments
US-based Poniard Pharmaceuticals has presented encouraging safety data from a Phase I dose-escalation study of picoplatin for the treatment of colorectal cancer.
The data presented at the 2008 Gastrointestinal Cancers Symposium included safety data from a Phase I study of picoplatin in combination with 5-fluorouracil (5FU) and leucovorin (LV) as a first-line treatment for metastatic colorectal [...]
January 29th, 2008 | Posted in Cancer drugs, Drugs and Medications, Poniard Pharmaceuticals, Research | No Comments
GlaxoSmithKline Plc announced further clinical trial results on Sunday underlining the ability of a drug combination including its product Tykerb to fight breast cancer that has spread to the brain.
An extension to an earlier Phase II study involving 49 patients showed 20 percent of those receiving a mix of Tykerb and Roche’s Xeloda experienced at [...]
December 26th, 2007 | Posted in Cancer drugs, Drugs and Medications, GlaxoSmithCline | No Comments
Pharmion Corporation (Nasdaq: PHRM) released interim findings from its Phase 2 trial of Amrubicin in second-line chemo-sensitive small cell lung cancer (SCLC). Amrubicin, the company’s third-generation synthetic anthracycline, is a potent topoisomerase II inhibitor currently in development for the treatment of SCLC. These findings indicate favorable interim results in terms of response rate and survival [...]
November 10th, 2007 | Posted in Cancer drugs, Drugs and Medications, New drugs, Pharmion, Research | No Comments
Merck, the manufacturer of the quadrivalent HPV vaccine Gardasil, already being administered in many countries to girls as young as 12 to help prevent cervical cancer, has announced findings of a trial that shows it is also effective for women as old as 45.
The drugmaker announced details of an investigational study where Gardasil reduced the [...]
November 6th, 2007 | Posted in Cancer drugs, Drugs and Medications, Vaccines | 3 Comments
A phase II trial on axitinib, a new experimental drug for treating patients with cytokine-refractory, metastatic kidney cancer who have a poor response to more traditional drugs has shown promising results according to a new study published in the The Lancet Oncology.
Professor Olivier Rixe of the University of Paris, France, and colleagues assessed the activity [...]
October 30th, 2007 | Posted in Cancer drugs, Drugs and Medications, New drugs, Research | No Comments